Cargando…
Upregulation of AXL and β-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance
Autores principales: | Sinha, Sutapa, Secreto, Charla R., Boysen, Justin C., Lesnick, Connie, Wang, Zhiquan, Ding, Wei, Call, Timothy G., Kenderian, Saad J., Parikh, Sameer A., Warner, Steven L., Bearss, David J., Ghosh, Asish K., Kay, Neil E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893033/ https://www.ncbi.nlm.nih.gov/pubmed/33602892 http://dx.doi.org/10.1038/s41408-021-00426-2 |
Ejemplares similares
-
Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy
por: Sinha, Sutapa, et al.
Publicado: (2018) -
SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis
por: Maiti, Guru P., et al.
Publicado: (2021) -
Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome
por: Wang, Yucai, et al.
Publicado: (2021) -
B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells
por: Wang, Zhiquan, et al.
Publicado: (2022) -
Transcriptional upregulation of c‐MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma
por: Hong, Jun, et al.
Publicado: (2018)